Speech Therapy Pediatric denied as experimental or investigational by Cigna?
An experimental denial requires the appeal to cite the FDA approval (if any), peer-reviewed phase III data, and the recognised specialty-society guideline that supports the treatment for your indication.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
Cigna's specific coverage criteria for speech therapy pediatric are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Cigna angle on Speech Therapy Pediatric
## Why Cigna Denies Pediatric Speech Therapy as Experimental
An "experimental or investigational" denial for pediatric speech therapy is unusual and almost always reflects either a miscoding issue or a denial applied to a specific technique or modality within speech therapy rather than to speech therapy as a whole. Standard pediatric speech-language pathology is a well-established, evidence-supported clinical discipline recognized by every major professional and medical body. It is not experimental.
When Cigna applies this label, the denial letter should specify exactly what technique, protocol, or modality it considers experimental. Common targets include newer augmentative and alternative communication (AAC) devices, specific intensive therapy protocols, or particular technology-assisted approaches. The appeal strategy depends on what Cigna is calling experimental.
## Immediate Steps
Obtain the complete written denial from Cigna citing the specific service, procedure code, and the policy language used to classify it as experimental. Request Cigna's current coverage policy document for the service. This is essential before drafting the appeal.
## Your Appeal Rights
- Internal appeal (ACA §2719 / ERISA §503): File a written appeal with clinical evidence supporting the established nature of the specific service. Cigna must review all submitted evidence.
- External review: After internal denial, request independent external review by an IRO — file within the deadline on your Explanation of Benefits, typically approximately four months. External reviewers apply broadly accepted medical evidence standards, not the plan's internal experimental/investigational definitions, and this is an area where external review frequently reverses plan decisions.
- Expedited review: For a child at a critical developmental period, delay of speech therapy can cause lasting harm. Document the developmental urgency and invoke expedited review.
- Mental Health Parity (MHPAEA): If the child's speech disorder is associated with autism or a behavioral health condition, parity law applies and requires Cigna to justify any more-restrictive limitation compared to analogous medical services.
## Documentation to Gather
1. Diagnosis and clinical necessity: The treating SLP's diagnosis documentation, referral, and treatment plan. 2. Evidence of established practice: A letter from the SLP citing that the specific technique is consistent with current practice guidelines from the American Speech-Language-Hearing Association (ASHA) or relevant clinical body — without quoting statistics, note that ASHA recognizes the approach as evidence-informed practice. 3. Professional society position statements: ASHA and the American Academy of Pediatrics (AAP) have published position statements on pediatric speech therapy that support established practice. Reference the organizations. 4. Peer-reviewed literature summary: The prescribing clinician can summarize (without statistics) that published peer-reviewed literature supports the approach — the IRO can evaluate the literature itself. 5. Prior authorization and claims history: If the same service was covered in prior periods, include that claims history — inconsistent application of the experimental label is a strong appeal argument.
## Criteria-Mapping Structure
Obtain Cigna's experimental/investigational policy for the specific service code. Copy each criterion for "established" status. Map each against the clinical evidence and professional guidelines. Explicitly address why the service meets the "established" standard under each criterion.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →